RapamycinFungusV1, Main, Exploration, bibRecord, 000357

Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.

Identifieur interne : 000357 ( Main/Exploration ); précédent : 000356; suivant : 000358

Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.

Auteurs : Adam X. Sang [États-Unis] ; Marla C. Mcpherson [États-Unis] ; Geoffrey T. Ivison [États-Unis] ; Xiumei Qu [États-Unis] ; Joseph Rigdon [États-Unis] ; Carlos O. Esquivel [États-Unis] ; Sheri M. Krams [États-Unis] ; Olivia M. Martinez [États-Unis]

Source :

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [ 1600-6143 ] ; 2019.

RBID : pubmed:30549430

Descripteurs français

KwdFr :
- Allogreffes (MeSH), Animaux (MeSH), Complications postopératoires (prévention et contrôle), Composés hétérocycliques 3 noyaux (administration et posologie), Concentration inhibitrice 50 (MeSH), Femelle (MeSH), Humains (MeSH), Infections à virus Epstein-Barr (prévention et contrôle), Lymphocytes B (MeSH), Lymphome B (prévention et contrôle), Lymphome B (virologie), Mâle (MeSH), Protéines proto-oncogènes c-akt (antagonistes et inhibiteurs), Purines (administration et posologie), Quinazolinones (administration et posologie), Rejet du greffon (MeSH), Sirolimus (administration et posologie), Souris (MeSH), Souris SCID (MeSH), Souris de lignée C57BL (MeSH), Souris de lignée NOD (MeSH), Survie du greffon (MeSH), Syndromes lymphoprolifératifs (prévention et contrôle), Syndromes lymphoprolifératifs (virologie), Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Transplantation cardiaque (effets indésirables), Transplantation cardiaque (méthodes), Transplantation d'organe (MeSH), Transplantation tumorale (MeSH).
MESH :
- administration et posologie : Composés hétérocycliques 3 noyaux, Purines, Quinazolinones, Sirolimus.
- antagonistes et inhibiteurs : Protéines proto-oncogènes c-akt, Sérine-thréonine kinases TOR.
- effets indésirables : Transplantation cardiaque.
- méthodes : Transplantation cardiaque.
- prévention et contrôle : Complications postopératoires, Infections à virus Epstein-Barr, Lymphome B, Syndromes lymphoprolifératifs.
- virologie : Lymphome B, Syndromes lymphoprolifératifs.
- Allogreffes, Animaux, Concentration inhibitrice 50, Femelle, Humains, Lymphocytes B, Mâle, Rejet du greffon, Souris, Souris SCID, Souris de lignée C57BL, Souris de lignée NOD, Survie du greffon, Transplantation d'organe, Transplantation tumorale.

English descriptors

KwdEn :
- Allografts (MeSH), Animals (MeSH), B-Lymphocytes (MeSH), Epstein-Barr Virus Infections (prevention & control), Female (MeSH), Graft Rejection (MeSH), Graft Survival (MeSH), Heart Transplantation (adverse effects), Heart Transplantation (methods), Heterocyclic Compounds, 3-Ring (administration & dosage), Humans (MeSH), Inhibitory Concentration 50 (MeSH), Lymphoma, B-Cell (prevention & control), Lymphoma, B-Cell (virology), Lymphoproliferative Disorders (prevention & control), Lymphoproliferative Disorders (virology), Male (MeSH), Mice (MeSH), Mice, Inbred C57BL (MeSH), Mice, Inbred NOD (MeSH), Mice, SCID (MeSH), Neoplasm Transplantation (MeSH), Organ Transplantation (MeSH), Phosphoinositide-3 Kinase Inhibitors (administration & dosage), Postoperative Complications (prevention & control), Proto-Oncogene Proteins c-akt (antagonists & inhibitors), Purines (administration & dosage), Quinazolinones (administration & dosage), Sirolimus (administration & dosage), TOR Serine-Threonine Kinases (antagonists & inhibitors).
MESH :
- chemical , administration & dosage : Heterocyclic Compounds, 3-Ring, Phosphoinositide-3 Kinase Inhibitors, Purines, Quinazolinones, Sirolimus.
- adverse effects : Heart Transplantation.
- chemical , antagonists & inhibitors : Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases.
- methods : Heart Transplantation.
- prevention & control : Epstein-Barr Virus Infections, Lymphoma, B-Cell, Lymphoproliferative Disorders, Postoperative Complications.
- virology : Lymphoma, B-Cell, Lymphoproliferative Disorders.
- Allografts, Animals, B-Lymphocytes, Female, Graft Rejection, Graft Survival, Humans, Inhibitory Concentration 50, Male, Mice, Mice, Inbred C57BL, Mice, Inbred NOD, Mice, SCID, Neoplasm Transplantation, Organ Transplantation.

Abstract

Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation that often manifests as Epstein-Barr virus (EBV)-associated B cell lymphomas. Current treatments for PTLD have limited efficacy and can be associated with graft rejection or systemic toxicities. The mTOR inhibitor, rapamycin, suppresses tumor growth of EBV+ B cell lymphoma cells in vitro and in vivo; however, the efficacy is limited and clinical benefits of mTOR inhibitors for PTLD are variable. Here, we show constitutive activation of multiple nodes within the PI3K/Akt/mTOR pathway in EBV+ PTLD-derived cell lines. Inhibition of either PI3K or Akt, with specific inhibitors CAL-101 and MK-2206, respectively, diminished growth of EBV+ B cell lines from PTLD patients in a dose-dependent manner. Importantly, rapamycin combined with CAL-101 or MK-2206 had a synergistic effect in suppressing cell growth as determined by IC₅₀ isobolographic analysis and Loewe indices. Moreover, these combinations were significantly more effective than rapamycin alone in inhibiting tumor xenograft growth in NOD-SCID mice. Finally, both CAL-101 and MK-2206 also prolonged survival of heterotopic cardiac allografts in C57BL/6 mice. Thus, combination therapy with rapamycin and a PI3K inhibitor, or an Akt inhibitor, can be an efficacious treatment for EBV-associated PTLD, while simultaneously promoting allograft survival.

DOI: 10.1111/ajt.15216
PubMed: 30549430
PubMed Central: PMC6482059

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000390
to stream Main, to step Curation: 000390

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.</title>
<author><name sortKey="Sang, Adam X" sort="Sang, Adam X" uniqKey="Sang A" first="Adam X" last="Sang">Adam X. Sang</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Surgery, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mcpherson, Marla C" sort="Mcpherson, Marla C" uniqKey="Mcpherson M" first="Marla C" last="Mcpherson">Marla C. Mcpherson</name>
<affiliation wicri:level="2"><nlm:affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Stanford Immunology, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ivison, Geoffrey T" sort="Ivison, Geoffrey T" uniqKey="Ivison G" first="Geoffrey T" last="Ivison">Geoffrey T. Ivison</name>
<affiliation wicri:level="2"><nlm:affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Stanford Immunology, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Qu, Xiumei" sort="Qu, Xiumei" uniqKey="Qu X" first="Xiumei" last="Qu">Xiumei Qu</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Surgery, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rigdon, Joseph" sort="Rigdon, Joseph" uniqKey="Rigdon J" first="Joseph" last="Rigdon">Joseph Rigdon</name>
<affiliation wicri:level="2"><nlm:affiliation>Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Quantitative Sciences Unit, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Esquivel, Carlos O" sort="Esquivel, Carlos O" uniqKey="Esquivel C" first="Carlos O" last="Esquivel">Carlos O. Esquivel</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Surgery, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Krams, Sheri M" sort="Krams, Sheri M" uniqKey="Krams S" first="Sheri M" last="Krams">Sheri M. Krams</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Surgery, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Stanford Immunology, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Martinez, Olivia M" sort="Martinez, Olivia M" uniqKey="Martinez O" first="Olivia M" last="Martinez">Olivia M. Martinez</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Surgery, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Stanford Immunology, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30549430</idno>
<idno type="pmid">30549430</idno>
<idno type="doi">10.1111/ajt.15216</idno>
<idno type="pmc">PMC6482059</idno>
<idno type="wicri:Area/Main/Corpus">000390</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000390</idno>
<idno type="wicri:Area/Main/Curation">000390</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000390</idno>
<idno type="wicri:Area/Main/Exploration">000390</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.</title>
<author><name sortKey="Sang, Adam X" sort="Sang, Adam X" uniqKey="Sang A" first="Adam X" last="Sang">Adam X. Sang</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Surgery, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mcpherson, Marla C" sort="Mcpherson, Marla C" uniqKey="Mcpherson M" first="Marla C" last="Mcpherson">Marla C. Mcpherson</name>
<affiliation wicri:level="2"><nlm:affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Stanford Immunology, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ivison, Geoffrey T" sort="Ivison, Geoffrey T" uniqKey="Ivison G" first="Geoffrey T" last="Ivison">Geoffrey T. Ivison</name>
<affiliation wicri:level="2"><nlm:affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Stanford Immunology, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Qu, Xiumei" sort="Qu, Xiumei" uniqKey="Qu X" first="Xiumei" last="Qu">Xiumei Qu</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Surgery, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rigdon, Joseph" sort="Rigdon, Joseph" uniqKey="Rigdon J" first="Joseph" last="Rigdon">Joseph Rigdon</name>
<affiliation wicri:level="2"><nlm:affiliation>Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Quantitative Sciences Unit, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Esquivel, Carlos O" sort="Esquivel, Carlos O" uniqKey="Esquivel C" first="Carlos O" last="Esquivel">Carlos O. Esquivel</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Surgery, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Krams, Sheri M" sort="Krams, Sheri M" uniqKey="Krams S" first="Sheri M" last="Krams">Sheri M. Krams</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Surgery, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Stanford Immunology, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Martinez, Olivia M" sort="Martinez, Olivia M" uniqKey="Martinez O" first="Olivia M" last="Martinez">Olivia M. Martinez</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Surgery, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Stanford Immunology, Stanford University School of Medicine, Stanford</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</title>
<idno type="eISSN">1600-6143</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Allografts (MeSH)</term>
<term>Animals (MeSH)</term>
<term>B-Lymphocytes (MeSH)</term>
<term>Epstein-Barr Virus Infections (prevention & control)</term>
<term>Female (MeSH)</term>
<term>Graft Rejection (MeSH)</term>
<term>Graft Survival (MeSH)</term>
<term>Heart Transplantation (adverse effects)</term>
<term>Heart Transplantation (methods)</term>
<term>Heterocyclic Compounds, 3-Ring (administration & dosage)</term>
<term>Humans (MeSH)</term>
<term>Inhibitory Concentration 50 (MeSH)</term>
<term>Lymphoma, B-Cell (prevention & control)</term>
<term>Lymphoma, B-Cell (virology)</term>
<term>Lymphoproliferative Disorders (prevention & control)</term>
<term>Lymphoproliferative Disorders (virology)</term>
<term>Male (MeSH)</term>
<term>Mice (MeSH)</term>
<term>Mice, Inbred C57BL (MeSH)</term>
<term>Mice, Inbred NOD (MeSH)</term>
<term>Mice, SCID (MeSH)</term>
<term>Neoplasm Transplantation (MeSH)</term>
<term>Organ Transplantation (MeSH)</term>
<term>Phosphoinositide-3 Kinase Inhibitors (administration & dosage)</term>
<term>Postoperative Complications (prevention & control)</term>
<term>Proto-Oncogene Proteins c-akt (antagonists & inhibitors)</term>
<term>Purines (administration & dosage)</term>
<term>Quinazolinones (administration & dosage)</term>
<term>Sirolimus (administration & dosage)</term>
<term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Allogreffes (MeSH)</term>
<term>Animaux (MeSH)</term>
<term>Complications postopératoires (prévention et contrôle)</term>
<term>Composés hétérocycliques 3 noyaux (administration et posologie)</term>
<term>Concentration inhibitrice 50 (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à virus Epstein-Barr (prévention et contrôle)</term>
<term>Lymphocytes B (MeSH)</term>
<term>Lymphome B (prévention et contrôle)</term>
<term>Lymphome B (virologie)</term>
<term>Mâle (MeSH)</term>
<term>Protéines proto-oncogènes c-akt (antagonistes et inhibiteurs)</term>
<term>Purines (administration et posologie)</term>
<term>Quinazolinones (administration et posologie)</term>
<term>Rejet du greffon (MeSH)</term>
<term>Sirolimus (administration et posologie)</term>
<term>Souris (MeSH)</term>
<term>Souris SCID (MeSH)</term>
<term>Souris de lignée C57BL (MeSH)</term>
<term>Souris de lignée NOD (MeSH)</term>
<term>Survie du greffon (MeSH)</term>
<term>Syndromes lymphoprolifératifs (prévention et contrôle)</term>
<term>Syndromes lymphoprolifératifs (virologie)</term>
<term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term>
<term>Transplantation cardiaque (effets indésirables)</term>
<term>Transplantation cardiaque (méthodes)</term>
<term>Transplantation d'organe (MeSH)</term>
<term>Transplantation tumorale (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Heterocyclic Compounds, 3-Ring</term>
<term>Phosphoinositide-3 Kinase Inhibitors</term>
<term>Purines</term>
<term>Quinazolinones</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Composés hétérocycliques 3 noyaux</term>
<term>Purines</term>
<term>Quinazolinones</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Heart Transplantation</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines proto-oncogènes c-akt</term>
<term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Proto-Oncogene Proteins c-akt</term>
<term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Transplantation cardiaque</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Heart Transplantation</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Transplantation cardiaque</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Epstein-Barr Virus Infections</term>
<term>Lymphoma, B-Cell</term>
<term>Lymphoproliferative Disorders</term>
<term>Postoperative Complications</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Complications postopératoires</term>
<term>Infections à virus Epstein-Barr</term>
<term>Lymphome B</term>
<term>Syndromes lymphoprolifératifs</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Lymphome B</term>
<term>Syndromes lymphoprolifératifs</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lymphoma, B-Cell</term>
<term>Lymphoproliferative Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Allografts</term>
<term>Animals</term>
<term>B-Lymphocytes</term>
<term>Female</term>
<term>Graft Rejection</term>
<term>Graft Survival</term>
<term>Humans</term>
<term>Inhibitory Concentration 50</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred C57BL</term>
<term>Mice, Inbred NOD</term>
<term>Mice, SCID</term>
<term>Neoplasm Transplantation</term>
<term>Organ Transplantation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Allogreffes</term>
<term>Animaux</term>
<term>Concentration inhibitrice 50</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphocytes B</term>
<term>Mâle</term>
<term>Rejet du greffon</term>
<term>Souris</term>
<term>Souris SCID</term>
<term>Souris de lignée C57BL</term>
<term>Souris de lignée NOD</term>
<term>Survie du greffon</term>
<term>Transplantation d'organe</term>
<term>Transplantation tumorale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation that often manifests as Epstein-Barr virus (EBV)-associated B cell lymphomas. Current treatments for PTLD have limited efficacy and can be associated with graft rejection or systemic toxicities. The mTOR inhibitor, rapamycin, suppresses tumor growth of EBV+ B cell lymphoma cells in vitro and in vivo; however, the efficacy is limited and clinical benefits of mTOR inhibitors for PTLD are variable. Here, we show constitutive activation of multiple nodes within the PI3K/Akt/mTOR pathway in EBV+ PTLD-derived cell lines. Inhibition of either PI3K or Akt, with specific inhibitors CAL-101 and MK-2206, respectively, diminished growth of EBV+ B cell lines from PTLD patients in a dose-dependent manner. Importantly, rapamycin combined with CAL-101 or MK-2206 had a synergistic effect in suppressing cell growth as determined by IC<sub>50</sub>
 isobolographic analysis and Loewe indices. Moreover, these combinations were significantly more effective than rapamycin alone in inhibiting tumor xenograft growth in NOD-SCID mice. Finally, both CAL-101 and MK-2206 also prolonged survival of heterotopic cardiac allografts in C57BL/6 mice. Thus, combination therapy with rapamycin and a PI3K inhibitor, or an Akt inhibitor, can be an efficacious treatment for EBV-associated PTLD, while simultaneously promoting allograft survival.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30549430</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>08</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-6143</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>19</Volume>
<Issue>5</Issue>
<PubDate><Year>2019</Year>
<Month>05</Month>
</PubDate>
</JournalIssue>
<Title>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</Title>
<ISOAbbreviation>Am J Transplant</ISOAbbreviation>
</Journal>
<ArticleTitle>Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.</ArticleTitle>
<Pagination><MedlinePgn>1305-1314</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/ajt.15216</ELocationID>
<Abstract><AbstractText>Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation that often manifests as Epstein-Barr virus (EBV)-associated B cell lymphomas. Current treatments for PTLD have limited efficacy and can be associated with graft rejection or systemic toxicities. The mTOR inhibitor, rapamycin, suppresses tumor growth of EBV+ B cell lymphoma cells in vitro and in vivo; however, the efficacy is limited and clinical benefits of mTOR inhibitors for PTLD are variable. Here, we show constitutive activation of multiple nodes within the PI3K/Akt/mTOR pathway in EBV+ PTLD-derived cell lines. Inhibition of either PI3K or Akt, with specific inhibitors CAL-101 and MK-2206, respectively, diminished growth of EBV+ B cell lines from PTLD patients in a dose-dependent manner. Importantly, rapamycin combined with CAL-101 or MK-2206 had a synergistic effect in suppressing cell growth as determined by IC<sub>50</sub>
 isobolographic analysis and Loewe indices. Moreover, these combinations were significantly more effective than rapamycin alone in inhibiting tumor xenograft growth in NOD-SCID mice. Finally, both CAL-101 and MK-2206 also prolonged survival of heterotopic cardiac allografts in C57BL/6 mice. Thus, combination therapy with rapamycin and a PI3K inhibitor, or an Akt inhibitor, can be an efficacious treatment for EBV-associated PTLD, while simultaneously promoting allograft survival.</AbstractText>
<CopyrightInformation>© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sang</LastName>
<ForeName>Adam X</ForeName>
<Initials>AX</Initials>
<Identifier Source="ORCID">0000-0002-6551-493X</Identifier>
<AffiliationInfo><Affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McPherson</LastName>
<ForeName>Marla C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo><Affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ivison</LastName>
<ForeName>Geoffrey T</ForeName>
<Initials>GT</Initials>
<AffiliationInfo><Affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Qu</LastName>
<ForeName>Xiumei</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rigdon</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Esquivel</LastName>
<ForeName>Carlos O</ForeName>
<Initials>CO</Initials>
<AffiliationInfo><Affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Krams</LastName>
<ForeName>Sheri M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo><Affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martinez</LastName>
<ForeName>Olivia M</ForeName>
<Initials>OM</Initials>
<AffiliationInfo><Affiliation>Department of Surgery, Stanford University School of Medicine, Stanford, California.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Stanford Immunology, Stanford University School of Medicine, Stanford, California.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 AI113130</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 AI007290</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>UL1 TR001085</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>01</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Am J Transplant</MedlineTA>
<NlmUniqueID>100968638</NlmUniqueID>
<ISSNLinking>1600-6135</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C548887">MK 2206</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011687">Purines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052999">Quinazolinones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="C514862">Akt1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>YG57I8T5M0</RegistryNumber>
<NameOfSubstance UI="C552946">idelalisib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D064591" MajorTopicYN="N">Allografts</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020031" MajorTopicYN="N">Epstein-Barr Virus Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006085" MajorTopicYN="Y">Graft Survival</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016027" MajorTopicYN="N">Heart Transplantation</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016393" MajorTopicYN="N">Lymphoma, B-Cell</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008232" MajorTopicYN="N">Lymphoproliferative Disorders</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016377" MajorTopicYN="N">Organ Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D052999" MajorTopicYN="N">Quinazolinones</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">basic (laboratory) research/science</Keyword>
<Keyword MajorTopicYN="Y">immunosuppressant-mechanistic target of rapamycin (mTOR)</Keyword>
<Keyword MajorTopicYN="Y">immunosuppression/immune modulation</Keyword>
<Keyword MajorTopicYN="Y">infection and infectious agents-viral: Epstein-Barr Virus (EBV)</Keyword>
<Keyword MajorTopicYN="Y">infectious disease</Keyword>
<Keyword MajorTopicYN="Y">posttransplant lymphoproliferative disorder (PTLD)</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>09</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>11</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>11</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30549430</ArticleId>
<ArticleId IdType="doi">10.1111/ajt.15216</ArticleId>
<ArticleId IdType="pmc">PMC6482059</ArticleId>
<ArticleId IdType="mid">NIHMS1002056</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nat Rev Dis Primers. 2016 Jan 28;2:15088</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27189056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Oncol. 2015 Jul;32(7):206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26087957</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2012 Jan 15;93(1):73-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22129761</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Haematol. 2008 Oct;81(4):298-303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18573174</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2009 Mar 20;284(12):8023-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19150980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Biol Ther. 2008 Dec;7(12):1952-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18981735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2004 May 15;77(9):1319-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15167584</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Stat Med. 2008 Mar 30;27(7):1040-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17768754</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2010 Aug 1;20(15):4308-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20561789</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1997 May 1;158(9):4045-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9126962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Hematol Malig Rep. 2013 Sep;8(3):173-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23737188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Cancer Res. 2015 Apr 15;5(5):1602-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26175931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Cycle. 2013 Jun 15;12(12):1892-900</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23676220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Rev Oncol Hematol. 2005 Oct;56(1):47-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16039868</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Clin Pathol. 2012 Oct;138(4):568-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23010712</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem J. 2012 Mar 15;442(3):465-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22364281</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lab Invest. 2007 Jan;87(1):29-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17075574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transl Res. 2010 Jan 01;2(1):19-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20182580</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2008 Sep;118(9):3065-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18725988</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2017 Mar;101(3):524-530</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27893611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Biol. 2009 Feb 10;7(2):e38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19209957</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Wound J. 2013 Feb;10(1):98-104</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22364410</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2007 Mar 22;26(13):1932-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17001314</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2013 Apr;13(4):883-890</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23398911</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cancer. 2015 Sep 16;6(12):1195-205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26535060</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2011 Oct 28;286(43):37368-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21908615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2012 Oct 27;94(8):879-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23001354</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 2006 May;47(5):e67-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16632009</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 1995 Aug 15;60(3):264-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7544036</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer. 2012 Nov 20;11:85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23167739</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2009 Apr 27;87(8 Suppl):S23-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19384183</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Oncol. 2010 Feb 20;28(6):1038-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20085936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2002 Oct;2(9):807-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12392286</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell Int. 2015 Sep 29;15:91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26421002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2017 Aug 10;170(4):605-635</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28802037</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biom J. 2008 Jun;50(3):346-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18481363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Transplant. 2012 May;16(3):220-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22353174</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2007 Dec 15;179(12):8225-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18056366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes. 2013 Aug;62(8):2674-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23881200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(8):e42610</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22880054</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10759564</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2013 Aug;13(8):2035-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23841834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2003 Aug 1;63(15):4472-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12907620</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2006 Apr 21;22(2):159-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16603397</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biometrics. 1997 Sep;53(3):983-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9333350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2007 Nov;7(11):2619-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17868060</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2007 Apr 27;83(8):1114-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17452903</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2003 May 27;75(10):1710-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12777861</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2011 Apr;11(4):751-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21446977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2017 Oct 16;8(1):951</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29038423</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2012 Jan 12;119(2):476-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22080480</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2012 May;12(5):1113-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22300508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Infect. 2015 Jun;21(6):604.e1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25686696</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Sang, Adam X" sort="Sang, Adam X" uniqKey="Sang A" first="Adam X" last="Sang">Adam X. Sang</name>
</region>
<name sortKey="Esquivel, Carlos O" sort="Esquivel, Carlos O" uniqKey="Esquivel C" first="Carlos O" last="Esquivel">Carlos O. Esquivel</name>
<name sortKey="Ivison, Geoffrey T" sort="Ivison, Geoffrey T" uniqKey="Ivison G" first="Geoffrey T" last="Ivison">Geoffrey T. Ivison</name>
<name sortKey="Krams, Sheri M" sort="Krams, Sheri M" uniqKey="Krams S" first="Sheri M" last="Krams">Sheri M. Krams</name>
<name sortKey="Krams, Sheri M" sort="Krams, Sheri M" uniqKey="Krams S" first="Sheri M" last="Krams">Sheri M. Krams</name>
<name sortKey="Martinez, Olivia M" sort="Martinez, Olivia M" uniqKey="Martinez O" first="Olivia M" last="Martinez">Olivia M. Martinez</name>
<name sortKey="Martinez, Olivia M" sort="Martinez, Olivia M" uniqKey="Martinez O" first="Olivia M" last="Martinez">Olivia M. Martinez</name>
<name sortKey="Mcpherson, Marla C" sort="Mcpherson, Marla C" uniqKey="Mcpherson M" first="Marla C" last="Mcpherson">Marla C. Mcpherson</name>
<name sortKey="Qu, Xiumei" sort="Qu, Xiumei" uniqKey="Qu X" first="Xiumei" last="Qu">Xiumei Qu</name>
<name sortKey="Rigdon, Joseph" sort="Rigdon, Joseph" uniqKey="Rigdon J" first="Joseph" last="Rigdon">Joseph Rigdon</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000357 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000357 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:30549430
   |texte=   Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:30549430" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.

Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki